Interleukin Genetics CEO Presents at Opening Session of EuroPerio 5 Meeting
07/05/2006
Interleukin Genetics CEO Presents at Opening Session of EuroPerio 5 Meeting
Waltham, MA, July 5, 2006 - Interleukin Genetics (AMEX: ILI) today announced that its Chief Executive Officer, Ken Kornman, DDS, PhD, presented during the Opening Session, "50 Years of Periodontology: From the Past to the Future" at the fifth triennial meeting of the European Federation of Periodontology in Madrid, Spain.
In his keynote address to over 4,000 participants, Dr. Kornman spoke about the technologies that will change the future of the practice of periodontics including the research by Interleukin Genetics’ involving its pioneering work in IL-1.
“We believe that the future of medicine and dentistry is preventive care and wellness instead of treatment of active disease processes. As individuals look forward to longer lifespans, they want to be well and active and will expect predictive and preventive medicine. For these reasons, there will be more emphasis on risk factors, such as genetics, in the prediction of who is likely to develop more aggressive periodontal disease and who will respond better to certain treatments,” commented Ken Kornman “We are leading in this effort at Interleukin through our research into the genetics of inflammation with our work in IL-1, where we have already developed DNA risk assessment tests for cardiovascular disease and for periodontitis.”
About Periodontal Disease
Periodontal disease is a bacterially induced inflammatory disease that destroys the bone and soft tissues that support the teeth and ultimately leads to tooth loss. Individuals with periodontal disease have been shown to also be at increased risk for certain diseases involving inflammation, including pre-term child birth and cardiovascular disease.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing and commercializing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin Genetics has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment, and its current development programs focus on osteoporosis, and weight management. Interleukin expects that these programs will also lead to products that will personalize the selection of nutritional and therapeutic products and enable the managed care industry to improve patient care and better allocate resources. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to complete all of our key milestones with regard to Alticor programs, our ability to make progress in advancing our core technologies and our ability to launch new commercial products and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Janet Perry
(781) 398-0700